The BMJ is an international peer reviewed medical journal and a fully “online first” publication. The BMJ’s vision is to be the world’s most influential and widely read medical journal. Our mission is to lead the debate on health and to engage, inform, and stimulate doctors, researchers, and other health professionals in ways that will improve outcomes for patients. We aim to help doctors to make better decisions.
4.17 RCTs for Cancer Drug Approval with Dr. Saroj Niraula & Myeloma Studies with Dr. Manni Mohyuddin
Manage episode 300860022 series 2547109
By Vinay Prasad, MD MPH, Vinay Prasad, and MD MPH. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.
We have two oncology conversations for you today. The first is with Dr. Saroj Niraula of the University of Manitoba, and together we discuss the necessity of randomized controlled trials for granting FDA approval of cancer drugs. The second is with Dr. Ghulam Rehman "Manni" Mohyuddin of the University of Utah on a variety of myeloma studies, including LIGHTHOUSE, OCEANS, and HORIZON. Feasibility of RCTs: doi.org/10.1093/jncics/pkab061 RR of Alternative Treatments: doi.org/10.1002/ijc.33231 Study Time Reduction: doi.org/10.1001/jamainternmed.2018.8351 Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew